https://www.selleckchem.com/products/ltx-315.html
To compare the effectiveness of oral fingolimod and conventional injectable disease-modifying agents (DMAs) using the composite endpoint of relapse or DMA treatment switch in patients with multiple sclerosis (MS). A retrospective longitudinal cohort study. IBM MarketScan Commercial Claims and Encounters Database from 2010-2012. Adults (≥18 years) with MS diagnosis (ICD-9-CM34 who newly initiated DMAs. Oral fingolimod and conventional injectable DMAs (interferon beta and glatiramer acetate). Composite endpoint of time to relapse or DMA
Like
Comment
Share
